Physician profile
William Bader
NPI 1871563411
$7,944.26
in general payments reported to CMS, 2019-2025
32 companies · $744 in 2025
The $744 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $790 · 2021: $1,276 · 2022: $1,249 · 2023: $1,511 · 2024: $966 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,156 · Education: $64.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.66 |
| Education | $64.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,740.54 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $962.48 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.77 | 2019-2023 | Jardiance, Stiolto Respimat, Tradjenta |
| Lilly USA, LLC | $708.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $516.88 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $508.92 | 2019-2024 | Ubrelvy, Qulipta |
| Pfizer INC. | $500.17 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $281.24 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $252.48 | 2021-2024 | |
| Abbott Laboratories | $244.31 | 2019-2024 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $221.61 | 2019-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $215.04 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $181.76 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $140.94 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $76.68 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.16 | 2019-2021 | |
| Verona Pharma, INC. | $61.23 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.85 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $58.12 | 2021 | |
| Lundbeck LLC | $54.67 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $45.67 | 2024 | Rexulti |
| Dexcom, INC. | $45.29 | 2022-2024 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $37.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.30 | 2024 | Eliquis |
| Allergan, INC. | $33.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.03 | 2019-2021 | |
| Boston Scientific Corporation | $24.83 | 2025 | Watchman Access System |
| Echosens North America, INC. | $16.45 | 2025 | Fibroscan |
| Edwards Lifesciences Corporation | $16.30 | 2025 | |
| Pulmonx Corporation | $14.80 | 2025 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.71 | 2025 | |
| Seqirus USA INC | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.